Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H30F3NO3 |
Molecular Weight | 377.4416 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCOC1=CC=C(CCC(N)(CO)CO)C=C1C(F)(F)F
InChI
InChIKey=JVCPIJKPAKAIIP-UHFFFAOYSA-N
InChI=1S/C19H30F3NO3/c1-2-3-4-5-6-11-26-17-8-7-15(12-16(17)19(20,21)22)9-10-18(23,13-24)14-25/h7-8,12,24-25H,2-6,9-11,13-14,23H2,1H3
Amiselimod (MT-1303) is a selective sphingosine 1-phosphate 1 (S1P1 ) receptor modulator which is currently being developed for the treatment of various autoimmune diseases. Unlike some other S1P receptor modulators, amiselimod seemed to show a favourable cardiac safety profile in preclinical, phase I and II studies. Amiselimod may be potentially useful for treatment of multiple sclerosis; inflammatory diseases; autoimmune diseases; psoriasis and inflammatory bowel diseases. Amiselimod is currently being developed by Mitsubishi Tanabe Pharma Corporation.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk. | 2017 Jan |
|
Evaluation and Optimization of in silico designed Sphingosine-1-Phosphate (S1P) Receptor Subtype 1 Modulators for the Management of Multiple Sclerosis. | 2017 Mar |
|
Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel-group, phase I study in healthy subjects. | 2017 May |
|
Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis. | 2018 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27921320
A total of 81 healthy subjects aged 18-55 years were equally randomized to receive amiselimod 0.4 mg, amiselimod 0.8 mg, placebo or fingolimod 0.5 mg once daily for 28 days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27714763
HEK293 cells or HCMs were plated onto 48-well culture plates, cultured
overnight and then incubated with 100 nmol/L of amiselimod for 3–12 h.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
10021
Created by
admin on Sat Dec 16 01:41:55 GMT 2023 , Edited by admin on Sat Dec 16 01:41:55 GMT 2023
|
PRIMARY | |||
|
358M5150LY
Created by
admin on Sat Dec 16 01:41:55 GMT 2023 , Edited by admin on Sat Dec 16 01:41:55 GMT 2023
|
PRIMARY | |||
|
300000037123
Created by
admin on Sat Dec 16 01:41:55 GMT 2023 , Edited by admin on Sat Dec 16 01:41:55 GMT 2023
|
PRIMARY | |||
|
942399-20-4
Created by
admin on Sat Dec 16 01:41:55 GMT 2023 , Edited by admin on Sat Dec 16 01:41:55 GMT 2023
|
PRIMARY | |||
|
DTXSID301141402
Created by
admin on Sat Dec 16 01:41:55 GMT 2023 , Edited by admin on Sat Dec 16 01:41:55 GMT 2023
|
PRIMARY | |||
|
CD-123
Created by
admin on Sat Dec 16 01:41:55 GMT 2023 , Edited by admin on Sat Dec 16 01:41:55 GMT 2023
|
PRIMARY | |||
|
16129483
Created by
admin on Sat Dec 16 01:41:55 GMT 2023 , Edited by admin on Sat Dec 16 01:41:55 GMT 2023
|
PRIMARY | |||
|
C166641
Created by
admin on Sat Dec 16 01:41:55 GMT 2023 , Edited by admin on Sat Dec 16 01:41:55 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD